Sysmex Inostics, a subsidiary of Sysmex, has signed an exclusive distributor agreement with IndivuTest and its parent company Indivumed, a cancer research company focused on the development of individualised cancer diagnostics and therapies. This collaboration will offer Sysmex Inostics OncoBEAM laboratory services throughout Germany, Austria and Switzerland.
Sysmex Inostics’ highly sensitive OncoBEAM services permit molecular genetic analysis of cell-free tumour DNA from blood or plasma, delivering an individualised approach to complement treatment decision-making in oncology. OncoBEAM, a non-invasive platform, reveals new possibilities for cancer management, while minimising costs and risks inherent with tissue biopsies.
The OncoBEAM assays target a wide variety of clinically actionable genetic mutations in cancers such as melanoma, colorectal, breast and lung tumours, delivering information in real-time to support therapy selection, detection of emergent mutations and assessment of drug response.
www.sysmex-inostics.com